Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,048,110.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $531.38, for a total value of $5,048,110.00. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $172,402,521.34. This represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $511.72 on Thursday. The firm has a market cap of $21.95 billion, a price-to-earnings ratio of 18.31, a price-to-earnings-growth ratio of 1.75 and a beta of 0.59. The company has a 50 day moving average price of $537.88 and a 200-day moving average price of $535.74. United Therapeutics Corporation has a 1-year low of $301.30 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same period in the prior year, the firm posted $6.41 earnings per share. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.32 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on UTHR shares. JPMorgan Chase & Co. lifted their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Bank of America cut their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Finally, TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in UTHR. Torren Management LLC purchased a new position in United Therapeutics during the fourth quarter worth approximately $26,000. Activest Wealth Management grew its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC increased its stake in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its stake in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics during the 4th quarter worth $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.